Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 90.79
Bid: 93.35
Ask: 93.36
Change: -0.20 (-0.22%)
Spread: 0.01 (0.011%)
Open: 92.56
High: 92.71
Low: 90.28
Prev. Close: 90.87
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

British equities slip on higher yields, financials drag

Tue, 02nd Jan 2024 17:05

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Marks and Spencer rises on ratings upgrade

*

AstraZeneca up as RSV infant shots approved in China

*

UK factory revival prospects suffer setback in Dec

Jan 2 (Reuters) - London stocks started the year on a sombre note, weighed down by losses in the financial sector and as UK government bond yields climbed to two-weeks high.

The blue-chip FTSE 100 fell 0.2% on Tuesday, after hitting an over seven-month high earlier in the session, while the mid-cap FTSE 250 index was down 0.9%.

Yields on the benchmark 10-year government bond rose over 15 basis points to 3.695%, touching a more than two-week high, tracking moves in U.S. Treasuries as investors moved away from higher risk assets.

The investment banking and brokerage services index led the losses with a 2.2% fall, closely followed by a 1.9% decline in life insurance stocks.

Meanwhile, the FTSE 100 completed its 40th trading year.

"The headline index has made almost no progress since the start of the century, and in the last decade the Footsie has been totally eclipsed by the U.S. stock market," said Laith Khalaf, head of investment analysis at AJ Bell.

Top performer pharma and biotech shares jumped 1.7%, supported by a 1.8% rise in AstraZeneca after the drugmaker's respiratory syncytial virus (RSV) immunisation for infants developed with Sanofi got approval in China.

Oil and gas shares added 0.4% as crude prices moved higher on the prospect of Middle Eastern supply disruptions after a naval clash in the Red Sea.

"Fundamentally, while supply continues to outstrip demand, the escalating hostilities in the Red Sea are raising concerns and providing support," said David Morrison, senior market analyst at Trade Nation.

Among individual movers, Marks and Spencer advanced 1.3% after Exane BNP Paribas raised the retailer's stock rating to "outperform" from "neutral".

Britain's manufacturing sector suffered a setback in its recovery efforts as output and employment fell more sharply in December than in the previous month, according to a survey.

Another set of data showed prices charged by British store chains rose at the slowest pace in a year and a half in December, an industry group said. (Reporting by Khushi Singh, Shubham Batra and Shashwat Chauhan in Bengaluru; Editing by Shinjini Ganguli and Mark Potter)

More News
10 Jun 2022 09:33

GSK closer to cracking elusive vaccine for common respiratory virus

LONDON, June 10 (Reuters) - GSK aims to get its respiratory syncytial virus (RSV) vaccine to regulators for review later this year, after interim data showed the vaccine was effective in a keenly-watched late-stage study involving older adults.

Read more
30 May 2022 17:34

European shares rise as China growth hopes boost luxury, tech stocks

May 30 (Reuters) - European shares touched their highest level in almost a month on Monday, with optimism buoyed by China's easing of COVID-19 restrictions and adding of new stimulus.

Read more
25 May 2022 11:03

French health body backs new COVID vaccine booster campaign for this autumn

PARIS, May 25 (Reuters) - France's Haute Autorite de Sante (HAS) health authority recommended preparing for a new vaccination campaign this autumn to give people aged 65 and older, and those with special health risks or conditions, access to a COVID-19 "booster" jab.

Read more
28 Apr 2022 16:17

Strong earnings spur rally across European stocks

April 28 (Reuters) - European shares moved further off six-week lows hit last session as forecast-beating results from companies including energy major TotalEnergies and automaker Volvo Car helped set aside worries about slowing global economic growth.

Read more
30 Mar 2022 09:01

What to own in uncertain times

WHAT TO OWN IN UNCERTAIN TIMES (0859 GMT)

Read more
17 Mar 2022 13:56

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert on Thursday said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and the start of July, potentially paving the way for approval this summer.

Read more
17 Mar 2022 13:34

EMA expects data on Omicron-specific vaccine as early as April

March 17 (Reuters) - The European Medicines Agency's (EMA) leading vaccine expert said that data on COVID-19 vaccines tailored for the Omicron variant should be available between April and July this year, potentially paving the way for a decision by the summer.

Read more
14 Mar 2022 10:18

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Sanofi's shares slid 5% on Monday after a drug candidate to fight a common type of breast cancer failed to slow progression of the disease in a clinical trial, knocking confidence in the French drugmaker's drug development prowess.

Read more
14 Mar 2022 09:11

Sanofi shares drop on trial setback for breast cancer pill

March 14 (Reuters) - Shares in Sanofi slumped 5.3% after an oral drug candidate to fight a common type of breast cancer that grows in response to oestrogen failed to slow progression of the disease in a clinical trial.

Read more
23 Feb 2022 15:31

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 12:44

Sanofi, GSK to seek approval for COVID vaccine candidate

PARIS, Feb 23 (Reuters) - French drugmaker Sanofi and its British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.

Read more
23 Feb 2022 10:22

Healthcare companies Sanofi and GSK to seek COVID-19 vaccine regulatory approval

PARIS, Feb 23 (Reuters) - Healthcare companies Sanofi and GSK said they intend to submit data from both their booster and Phase III efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Read more
18 Feb 2022 09:00

GSK pauses trial of respiratory virus vaccine in pregnant women

Feb 18 (Reuters) - GSK has paused a late-stage trial of its vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women based on safety recommendations from an independent committee, the British drugmaker said on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.